ReviewCureus2025
Breathing New Life Into Donation After Circulatory Death (DCD) Lung Transplantation: The Role of Machine Perfusion.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lung Ischemia-Reperfusion Injury in Lung Transplant Surgery: Where Do We Stand?Antioxidants (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung transplantation (LTx) is a life-saving procedure for patients with end-stage pulmonary disease, but the shortage of suitable donor lungs remains a critical barrier. Traditionally, lungs from donors after brain death (DBD) have been preferred, though the growing presence of donation after circulatory death (DCD) is a viable solution to expand the donor pool. However, DCD lungs present unique challenges, primarily due to exposure to warm ischemia, higher aspiration risk, hurried evaluation, and the lack of real-time viability assessment. Additionally, many donor hospitals and organ procurement organizations (OPOs) impose limitations on certain pre-mortem interventions, such as restrictions on aggressive lung recruitment, a potential barrier to improvement of lung function, and bronchoscopy, which can reduce the willingness of transplant centers to accept lung offers. This review examines the impact of modern preservation methods, particularly machine perfusion (MP) technologies such as ex vivo lung perfusion (EVLP) and the Organ Care System (OCS), on DCD lung transplantation outcomes. MP technologies allow for the preservation, assessment, and reconditioning of DCD lungs, significantly improving their viability and transplantation success rates. Studies indicate that MP can reduce the risks of ischemia-reperfusion injury (IRI), enhance graft function, and increase lung utilization without compromising short-term or long-term survival outcomes. Despite this, the implementation of MP faces challenges related to logistical coordination, cost-effectiveness, and protocol variability. With that said, the growing body of evidence suggests that MP can help to overcome the traditional limitations of DCD lungs, thus expanding the donor pool and improving transplant outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.